MovDisordV3, PascalFrancis, Corpus, bibRecord, 002903

Poetic talent unmasked by treatment of Parkinson's disease

Identifieur interne : 002903 ( PascalFrancis/Corpus ); précédent : 002902; suivant : 002904

Poetic talent unmasked by treatment of Parkinson's disease

Auteurs : Anette Schrag ; Michael Trimble

Source :

Movement disorders [ 0885-3185 ] ; 2001.

RBID : Pascal:02-0176264

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Lisuride, Lévodopa, Antiparkinsonien, Agoniste, Récepteur dopaminergique, Artiste, Etude cas, Evolution, Homme, Chimiothérapie, Poésie, Ergot dérivé.

English descriptors

KwdEn :
- Agonist, Antiparkinson agent, Artist, Case study, Chemotherapy, Dopamine receptor, Ergot derivatives, Evolution, Human, Levodopa, Lisuride, Parkinson disease, Poetry.

Abstract

Parkinson's disease is typically characterised by loss of function and previous abilities, often accompanied by complications of treatment in later stages of the disease. We report on a patient who newly developed an artistic skill after starting treatment for Parkinson's disease. This case offers insight into the neurology of the artistic process as well as into the pathophysiology of psychiatric adverse reactions to the treatment of PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 16`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Poetic talent unmasked by treatment of Parkinson's disease`
A11	`01`	`1`		`@1 SCHRAG (Anette)`
A11	`02`	`1`		`@1 TRIMBLE (Michael)`
A14	`01`			`@1 Raymond Way Neuropsychiatry Research Group, Institute of Neurology, University College London @2 London @3 GBR @Z 1 aut. @Z 2 aut.`
A20				`@1 1175-1176`
A21				`@1 2001`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000094252170270`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 8 ref.`
A47	`01`	`1`		`@0 02-0176264`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	`@0 Parkinson's disease is typically characterised by loss of function and previous abilities, often accompanied by complications of treatment in later stages of the disease. We report on a patient who newly developed an artistic skill after starting treatment for Parkinson's disease. This case offers insight into the neurology of the artistic process as well as into the pathophysiology of psychiatric adverse reactions to the treatment of PD.`
C02	`01`	`X`		`@0 002B02B06`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Lisuride @2 NK @2 FR @5 04`
C03	`02`	`X`	`ENG`	`@0 Lisuride @2 NK @2 FR @5 04`
C03	`02`	`X`	`SPA`	`@0 Lisurida @2 NK @2 FR @5 04`
C03	`03`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 07`
C03	`03`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 07`
C03	`03`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 07`
C03	`04`	`X`	`FRE`	`@0 Antiparkinsonien @5 08`
C03	`04`	`X`	`ENG`	`@0 Antiparkinson agent @5 08`
C03	`04`	`X`	`SPA`	`@0 Antiparkinsoniano @5 08`
C03	`05`	`X`	`FRE`	`@0 Agoniste @5 10`
C03	`05`	`X`	`ENG`	`@0 Agonist @5 10`
C03	`05`	`X`	`SPA`	`@0 Agonista @5 10`
C03	`06`	`X`	`FRE`	`@0 Récepteur dopaminergique @5 11`
C03	`06`	`X`	`ENG`	`@0 Dopamine receptor @5 11`
C03	`06`	`X`	`SPA`	`@0 Receptor dopaminérgico @5 11`
C03	`07`	`X`	`FRE`	`@0 Artiste @5 13`
C03	`07`	`X`	`ENG`	`@0 Artist @5 13`
C03	`07`	`X`	`SPA`	`@0 Artista @5 13`
C03	`08`	`X`	`FRE`	`@0 Etude cas @5 16`
C03	`08`	`X`	`ENG`	`@0 Case study @5 16`
C03	`08`	`X`	`SPA`	`@0 Estudio caso @5 16`
C03	`09`	`X`	`FRE`	`@0 Evolution @5 17`
C03	`09`	`X`	`ENG`	`@0 Evolution @5 17`
C03	`09`	`X`	`SPA`	`@0 Evolución @5 17`
C03	`10`	`X`	`FRE`	`@0 Homme @5 20`
C03	`10`	`X`	`ENG`	`@0 Human @5 20`
C03	`10`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`11`	`X`	`FRE`	`@0 Chimiothérapie @5 23`
C03	`11`	`X`	`ENG`	`@0 Chemotherapy @5 23`
C03	`11`	`X`	`SPA`	`@0 Quimioterapia @5 23`
C03	`12`	`X`	`FRE`	`@0 Poésie @5 24`
C03	`12`	`X`	`ENG`	`@0 Poetry @5 24`
C03	`12`	`X`	`SPA`	`@0 Poesía @5 24`
C03	`13`	`X`	`FRE`	`@0 Ergot dérivé @5 27`
C03	`13`	`X`	`ENG`	`@0 Ergot derivatives @5 27`
C03	`13`	`X`	`SPA`	`@0 Ergot derivado @5 27`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
N21				`@1 098`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 02-0176264 INIST
ET :	Poetic talent unmasked by treatment of Parkinson's disease
AU :	SCHRAG (Anette); TRIMBLE (Michael)
AF :	Raymond Way Neuropsychiatry Research Group, Institute of Neurology, University College London/London/Royaume-Uni (1 aut., 2 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2001; Vol. 16; No. 6; Pp. 1175-1176; Bibl. 8 ref.
LA :	Anglais
EA :	Parkinson's disease is typically characterised by loss of function and previous abilities, often accompanied by complications of treatment in later stages of the disease. We report on a patient who newly developed an artistic skill after starting treatment for Parkinson's disease. This case offers insight into the neurology of the artistic process as well as into the pathophysiology of psychiatric adverse reactions to the treatment of PD.
CC :	002B02B06; 002B17G
FD :	Parkinson maladie; Lisuride; Lévodopa; Antiparkinsonien; Agoniste; Récepteur dopaminergique; Artiste; Etude cas; Evolution; Homme; Chimiothérapie; Poésie; Ergot dérivé
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED :	Parkinson disease; Lisuride; Levodopa; Antiparkinson agent; Agonist; Dopamine receptor; Artist; Case study; Evolution; Human; Chemotherapy; Poetry; Ergot derivatives
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
SD :	Parkinson enfermedad; Lisurida; Levodopa; Antiparkinsoniano; Agonista; Receptor dopaminérgico; Artista; Estudio caso; Evolución; Hombre; Quimioterapia; Poesía; Ergot derivado
LO :	INIST-20953.354000094252170270
ID :	02-0176264

Links to Exploration step

Pascal:02-0176264

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Poetic talent unmasked by treatment of Parkinson's disease</title>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation><inist:fA14 i1="01"><s1>Raymond Way Neuropsychiatry Research Group, Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Trimble, Michael" sort="Trimble, Michael" uniqKey="Trimble M" first="Michael" last="Trimble">Michael Trimble</name>
<affiliation><inist:fA14 i1="01"><s1>Raymond Way Neuropsychiatry Research Group, Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0176264</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 02-0176264 INIST</idno>
<idno type="RBID">Pascal:02-0176264</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002903</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Poetic talent unmasked by treatment of Parkinson's disease</title>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation><inist:fA14 i1="01"><s1>Raymond Way Neuropsychiatry Research Group, Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Trimble, Michael" sort="Trimble, Michael" uniqKey="Trimble M" first="Michael" last="Trimble">Michael Trimble</name>
<affiliation><inist:fA14 i1="01"><s1>Raymond Way Neuropsychiatry Research Group, Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Artist</term>
<term>Case study</term>
<term>Chemotherapy</term>
<term>Dopamine receptor</term>
<term>Ergot derivatives</term>
<term>Evolution</term>
<term>Human</term>
<term>Levodopa</term>
<term>Lisuride</term>
<term>Parkinson disease</term>
<term>Poetry</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Lisuride</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique</term>
<term>Artiste</term>
<term>Etude cas</term>
<term>Evolution</term>
<term>Homme</term>
<term>Chimiothérapie</term>
<term>Poésie</term>
<term>Ergot dérivé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parkinson's disease is typically characterised by loss of function and previous abilities, often accompanied by complications of treatment in later stages of the disease. We report on a patient who newly developed an artistic skill after starting treatment for Parkinson's disease. This case offers insight into the neurology of the artistic process as well as into the pathophysiology of psychiatric adverse reactions to the treatment of PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>16</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Poetic talent unmasked by treatment of Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SCHRAG (Anette)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>TRIMBLE (Michael)</s1>
</fA11>
<fA14 i1="01"><s1>Raymond Way Neuropsychiatry Research Group, Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>1175-1176</s1>
</fA20>
<fA21><s1>2001</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000094252170270</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>8 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0176264</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Parkinson's disease is typically characterised by loss of function and previous abilities, often accompanied by complications of treatment in later stages of the disease. We report on a patient who newly developed an artistic skill after starting treatment for Parkinson's disease. This case offers insight into the neurology of the artistic process as well as into the pathophysiology of psychiatric adverse reactions to the treatment of PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lisuride</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Lisuride</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Lisurida</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Agonist</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Agonista</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Artiste</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Artist</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Artista</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Etude cas</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Case study</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estudio caso</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Evolution</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Evolution</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Evolución</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>23</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Poésie</s0>
<s5>24</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Poetry</s0>
<s5>24</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Poesía</s0>
<s5>24</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Ergot dérivé</s0>
<s5>27</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Ergot derivatives</s0>
<s5>27</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Ergot derivado</s0>
<s5>27</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>098</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 02-0176264 INIST</NO>
<ET>Poetic talent unmasked by treatment of Parkinson's disease</ET>
<AU>SCHRAG (Anette); TRIMBLE (Michael)</AU>
<AF>Raymond Way Neuropsychiatry Research Group, Institute of Neurology, University College London/London/Royaume-Uni (1 aut., 2 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2001; Vol. 16; No. 6; Pp. 1175-1176; Bibl. 8 ref.</SO>
<LA>Anglais</LA>
<EA>Parkinson's disease is typically characterised by loss of function and previous abilities, often accompanied by complications of treatment in later stages of the disease. We report on a patient who newly developed an artistic skill after starting treatment for Parkinson's disease. This case offers insight into the neurology of the artistic process as well as into the pathophysiology of psychiatric adverse reactions to the treatment of PD.</EA>
<CC>002B02B06; 002B17G</CC>
<FD>Parkinson maladie; Lisuride; Lévodopa; Antiparkinsonien; Agoniste; Récepteur dopaminergique; Artiste; Etude cas; Evolution; Homme; Chimiothérapie; Poésie; Ergot dérivé</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Lisuride; Levodopa; Antiparkinson agent; Agonist; Dopamine receptor; Artist; Case study; Evolution; Human; Chemotherapy; Poetry; Ergot derivatives</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<SD>Parkinson enfermedad; Lisurida; Levodopa; Antiparkinsoniano; Agonista; Receptor dopaminérgico; Artista; Estudio caso; Evolución; Hombre; Quimioterapia; Poesía; Ergot derivado</SD>
<LO>INIST-20953.354000094252170270</LO>
<ID>02-0176264</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002903 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002903 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:02-0176264
   |texte=   Poetic talent unmasked by treatment of Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Poetic talent unmasked by treatment of Parkinson's disease

Poetic talent unmasked by treatment of Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri